Stifel Financial Corp Atreca, Inc. Transaction History

Stifel Financial Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.88 - $1.22 $709 - $983	-806 Reduced 7.33%	10,191 $9,000
Q1 2023 May 12, 2023	BUY	$0.91 - $1.82 $10,007 - $20,014	10,997 New	10,997 $12,000
Q3 2022 Nov 14, 2022	BUY	$1.59 - $2.74 $2,917 - $5,027	1,835 Added 13.37%	15,562 $24,000
Q2 2022 Aug 15, 2022	BUY	$1.56 - $3.25 $1,277 - $2,661	819 Added 6.34%	13,727 $25,000
Q1 2022 May 13, 2022	SELL	$1.61 - $5.2 $10,964 - $35,412	-6,810 Reduced 34.54%	12,908 $41,000
Q4 2021 Feb 14, 2022	BUY	$2.87 - $6.29 $18,548 - $40,652	6,463 Added 48.76%	19,718 $60,000
Q3 2021 Nov 15, 2021	SELL	$4.91 - $9.07 $94,802 - $175,123	-19,308 Reduced 59.29%	13,255 $83,000
Q2 2021 Aug 13, 2021	BUY	$7.82 - $13.8 $54,935 - $96,945	7,025 Added 27.51%	32,563 $278,000
Q1 2021 May 14, 2021	BUY	$13.0 - $19.34 $57,876 - $86,101	4,452 Added 21.11%	25,538 $391,000
Q4 2020 Feb 12, 2021	SELL	$13.03 - $17.09 $11,205 - $14,697	-860 Reduced 3.92%	21,086 $340,000
Q3 2020 Nov 16, 2020	BUY	$12.67 - $23.19 $278,055 - $508,927	21,946 New	21,946 $307,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Stifel Financial Corp with notifications on news.